Oakes Benjamin L. 4
4 · Scribe Therapeutics, Inc. · Filed Jul 27, 2026
Research Summary
AI-generated summary of this filing
Scribe (SCTX) CEO Benjamin Oakes Receives Equity Awards
What Happened
Benjamin L. Oakes, President, CEO, Director and Chairman of Scribe Therapeutics (SCTX), was granted a total of 707,352 derivative shares/options in three awards: 12,969 shares on 2026-03-13 and two grants of 264,784 and 429,599 shares on 2026-07-23. All grants are reported at a $0.00 price (derivative awards), so these are compensation awards (options/RSUs or similar), not cash purchases or open-market sales.
Key Details
- Transactions reported:
- 2026-03-13: 12,969 shares awarded at $0.00 (derivative).
- 2026-07-23: 264,784 shares awarded at $0.00 (derivative).
- 2026-07-23: 429,599 shares awarded at $0.00 (derivative).
- Total awarded in this filing: 707,352 derivative shares/options.
- Shares owned after the transactions: not specified in the provided filing excerpt.
- Filing timeliness: Form 4 filed 2026-07-27 for transactions dated 2026-03-13 and 2026-07-23 — this indicates a delayed filing relative to the transaction dates.
- Notable footnotes:
- F1: Some transactions occurred prior to the issuer's registration in the IPO and are reported under Rule 16a-2(a).
- F2: One option is fully vested.
- F3: Certain options vest monthly as to 1/48 over four years, starting Aug 23, 2026, subject to continued service.
- F4: Some options vest only upon achievement of market-based performance criteria during July 23, 2026–July 23, 2029, subject to continued service.
Context
These are compensation grants (derivative securities) rather than open-market purchases or sales. Derivative awards do not convert into actual common stock until vesting/exercise conditions are met; some awards here are time‑based, some are performance‑based, and one is already fully vested per the footnotes. Awards are routine for executives as part of pay and retention and should not be interpreted alone as an immediate buy or sell signal.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1][F2]2026-03-13+12,969→ 12,969 totalExercise: $19.13Exp: 2036-03-12→ Common Stock (12,969 underlying) - Award
Stock Option (Right to Buy)
[F3]2026-07-23+264,784→ 264,784 totalExercise: $15.00Exp: 2036-07-22→ Common Stock (264,784 underlying) - Award
Performance-based Stock Option (Right to Buy)
[F4]2026-07-23+429,599→ 429,599 totalExercise: $15.00Exp: 2036-07-22→ Common Stock (429,599 underlying)
Footnotes (4)
- [F1]The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
- [F2]The option is fully vested.
- [F3]The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
- [F4]The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.